Almirall S.A. stock (ES0157097017): dermatology focus after latest quarterly update

Spanish dermatology specialist Almirall S.A. has recently reported quarterly results and updated its outlook, putting the focus on prescription skin treatments and its US growth ambitions. What matters now for investors watching the European pharma mid cap?

Spanish dermatology-focused pharmaceutical group Almirall S.A. recently reported its latest quarterly figures and reiterated its strategy to grow in medical dermatology, especially in Europe and the United States, according to a company earnings release published in 2025 on its investor relations site and coverage by European business media in early 2025. These updates keep attention on prescription skin therapies and the company’s late-stage pipeline in chronic inflammatory diseases such as atopic dermatitis and psoriasis, as reported by Almirall investor materials as of 03/20/2025 and European financial press coverage dated 03/21/2025.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall
• Sector/industry: Pharmaceutical / dermatology
• Headquarters/country: Barcelona, Spain
• Core markets: Europe and North America
• Key revenue drivers: Prescription dermatology therapies
• Home exchange/listing venue: BME Spanish Exchanges (ticker: ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall is a mid-sized, research-driven pharmaceutical company with a strategic focus on medical dermatology. The group develops, manufactures and commercializes prescription medicines that target chronic skin conditions, while its legacy portfolio still includes some non-dermatology products. Management has emphasized in several earnings updates that dermatology is the main growth engine for the company, with spending on R&D concentrated on inflammatory and autoimmune skin diseases, according to statements in an earnings presentation published on the firm’s website during 2024 and a related article from a Spanish financial daily on 02/29/2024.

The company’s operating model combines internal research and development with selective in-licensing and partnerships. In practice this means Almirall sometimes acquires regional rights to innovative dermatology drugs originally discovered by other biotech firms, while continuing to develop its own molecules across early and late clinical stages. This mixed model aims to balance pipeline risk and time to market, as highlighted in a capital markets presentation and summarized by European equity analysts in reports released during the first half of 2024, referenced by Almirall results documents as of 04/30/2024.

A significant portion of Almirall’s commercial infrastructure is focused on specialist physicians, especially dermatologists and allergists. The company operates dedicated sales forces in key European markets such as Germany, Spain, Italy and the UK, and maintains a presence in the United States, often alongside partners. This specialist focus differs from mass-market consumer skincare and requires continuous medical education, post-marketing studies and close interaction with hospital and clinic networks. In conference commentary, management has argued that this targeted approach supports higher barriers to entry in complex indications compared with purely cosmetic brands, as reported in a Q&A transcript shared with investors in 2024 by Almirall and summarized in a European healthcare sector review dated 05/10/2024.

Main revenue and product drivers for Almirall S.A.

Revenue at Almirall is largely generated by a portfolio of prescription dermatology brands addressing chronic inflammatory conditions. Key therapeutic areas include atopic dermatitis, psoriasis, acne and actinic keratosis, among others. In past financial reports, management has indicated that innovative launches in Europe have been offsetting erosion in some older products, leading to a higher share of specialty dermatology in total net sales for the year 2023, according to an annual report discussion section released in early 2024 and summarized by a European newswire on 03/01/2024.

Atopic dermatitis has emerged as a central pillar of the company’s growth narrative. Almirall has highlighted advanced-stage candidates and recently launched treatments aimed at moderate-to-severe patients who require systemic therapy, a segment where biologics and novel small molecules are reshaping standards of care. In its 2024 and 2025 earnings materials, management emphasised that market uptake of newer atopic dermatitis therapies and broader reimbursement coverage in major European markets could play a critical role in medium-term revenue trends, according to slides and commentary cited by Almirall financial reports as of 02/23/2025.

Plaque psoriasis and other chronic inflammatory skin conditions represent another important revenue driver. Almirall markets treatments designed for patients who have not responded sufficiently to traditional systemic therapies and who may not yet qualify for or respond to certain biologics. The company has previously reported that demand in European markets remained robust through 2023 and into early 2024, even as competition from larger global pharmaceutical rivals intensified. Meanwhile, the firm’s historic presence in actinic keratosis and acne therapeutics continues to contribute steady income, though growth is generally slower due to generic pressure, according to commentary from management during a 2024 conference call reported by a European news agency on 05/15/2024.

Beyond prescription dermatology, Almirall retains some non-core brands and older primary care products, particularly in its domestic Spanish market. However, the long-term strategic intention communicated to investors has been to reduce reliance on these legacy lines and prioritize capital allocation toward higher-margin specialist dermatology projects. This repositioning is reflected in the evolution of the product mix described in the company’s 2023 and 2024 annual reporting packages, where the share of net sales attributed to medical dermatology steadily increased compared with prior years, based on statements within the management discussion and analysis section released in early 2024 and referenced by European financial media as of 03/05/2024.

Industry trends and competitive position

The global dermatology pharmaceuticals market has been expanding as awareness of chronic skin diseases improves and patients seek more effective and convenient therapies. Inflammatory skin conditions such as atopic dermatitis, psoriasis and hidradenitis suppurativa are increasingly recognized as systemic diseases that affect quality of life and mental health. This trend has encouraged investment in biologics and targeted small molecules from large multinational drug makers as well as specialized mid-cap firms. Sector research published in 2024 by healthcare industry analysts and summarized in trade press articles indicated that dermatology remains one of the more attractive specialty areas for innovation due to high unmet need and growing diagnosis rates.

Within this environment, Almirall positions itself as a focused specialist with a strong European base rather than a diversified global pharmaceutical conglomerate. Its competitive set includes both large-cap pharmaceutical companies with broad immunology portfolios and other mid-sized dermatology-focused firms. Almirall’s advantage lies in its established commercial network in Europe, experience in topical and systemic dermatology, and willingness to partner in research and commercialization. However, the presence of larger competitors with significant financial resources means that maintaining differentiation through innovation, safety profiles and patient support services is critical, as highlighted in a sector overview by European brokers referencing Almirall’s strategy in mid-2024.

Pricing pressures in Europe and evolving reimbursement frameworks represent ongoing challenges. Health authorities and payers scrutinize cost-effectiveness data, particularly for novel biologic treatments, and generic competition can erode pricing power for older molecules. For a company like Almirall, which has a high exposure to European markets, successfully navigating these dynamics requires careful portfolio management, negotiation expertise and real-world evidence generation. Analysts have noted that the company’s increasing emphasis on specialty indications and newer therapies may provide some resilience against downward pricing pressure, but the macro environment remains an important factor for revenue visibility, as captured in commentary across 2024 research notes from European investment banks.

Why Almirall S.A. matters for US investors

For US-based investors, Almirall offers exposure to the European specialty pharmaceutical market, particularly in dermatology, through a company whose primary listing is on the Spanish stock exchange. While the stock is not a US domestic listing, American investors can still monitor and access the shares via international brokerage platforms that support trading on European exchanges. The company’s strategic ambition to grow in the United States adds further relevance, since US approvals and commercial partnerships could influence earnings and valuation over time, according to comments by management in 2024 when discussing the expansion of their dermatology footprint in North America.

US investors often look at international mid caps like Almirall to diversify beyond large US-based pharmaceutical giants, potentially gaining access to different regulatory environments, pricing structures and therapy portfolios. Given that chronic skin diseases are prevalent among US patients and represent a sizable portion of global dermatology demand, any successful launch of Almirall products in the US could have an outsized impact on total company sales compared with launches in smaller markets. This linkage between US clinical and commercial milestones and overall group performance has been highlighted in sector commentary by global healthcare strategists in 2024 and 2025, who emphasized that regulatory decisions by the US Food and Drug Administration (FDA) can be key catalysts even for non-US-listed biotech and pharma names.

Another angle for US investors is currency and macro diversification. Almirall reports in euros and generates most of its revenue in Europe, while seeking incremental growth in North America and other regions. For US-dollar-based portfolios, this can provide a different risk profile compared with US-only pharmaceutical holdings, as returns are influenced not only by company-specific execution but also by euro-dollar exchange movements and European healthcare policy trends. Such considerations are routinely discussed in cross-border portfolio research produced by global banks in 2024, underscoring why mid-cap European healthcare stocks like Almirall appear in international growth and defensive equity strategies.

Conclusion

Almirall S.A. has reinforced its positioning as a specialist in prescription dermatology, supported by recent quarterly results and ongoing investment in an inflammation-focused pipeline. The company’s strategy centers on expanding its presence in chronic skin diseases, especially atopic dermatitis and psoriasis, while gradually reducing dependence on older non-core products. For investors, the story combines opportunities in European and US dermatology markets with typical risks of mid-sized pharmaceutical players, including competitive pressure, regulatory uncertainty and pricing dynamics. As with any healthcare stock, outcomes for key late-stage candidates, reimbursement decisions and execution in priority markets will likely shape the long-term risk–reward profile.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.